Re: Celgene inks $1B deal for a preclinical epigenetic blood cancer drug from Canada.

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

BearDownAZ

Rank: President [?]

Points: 25003 [?]

Votes: 68 Score: 4.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Celgene inks $1B deal for a preclinical epigenetic blood cancer drug from Canada.

in response to

Re: Celgene inks $1B deal for a preclinical epigenetic blood cancer drug from Canada.

Toinv

posted on Feb 10, 2019 10:07PM

Toniv,

They left off the legend to the synergism graph in their most recent presentation. If you look at a prior presentation (i.e. slide 27 from this Jan 2017 presentation) you will see that the colors represent different types of cancers and the shapes/symbols represent different cancer cell lines for each cancer type. Synergy is greater the closer to 0. As for the apples vs. oranges symbolism in slide 8 of the January 2019 preentation......the message is that newer generation pan-BET inhibitors like ZEN-3694 are far superior in so many ways compared to older, first generation pan-BET inhibitors.